Kabra Drugs last traded at ₹18.35 (2026-10-13). Over the past month the stock moved -8.9%, three months the stock moved -24.2%, year the stock moved -5.4%. Its closing range over 52 weeks is ₹18.08 – ₹33.75, with the latest close 45.6% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]
Business Overview:[1] KDL is in the business of manufacturing Perma culture and trading in the pharma-related product.
In the latest quarter (Jun 2026), Kabra Drugs reported sales of ₹46.22 crore (+546.4%) and net profit of ₹2.12 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 46.22 | 2.79 | 6.04 | 2.12 | 0.89 |
| Mar 2026 | 35.41 | 1.34 | 3.78 | 1.06 | 0.45 |
| Dec 2025 | 30.42 | 2.43 | 7.99 | 2.57 | 1.08 |
| Sep 2025 | 19.76 | 2.04 | 10.32 | 1.84 | 0.78 |
| Jun 2025 | 7.15 | -0.52 | -7.27 | -0.50 | -0.21 |
| Mar 2025 | 0.00 | -0.24 | – | 0.39 | 0.16 |
| Dec 2024 | 0.00 | -0.53 | – | -0.54 | -0.54 |
| Sep 2024 | 0.00 | -0.40 | – | -0.40 | -0.40 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | – | – | – | – | – | – | – | +546.4% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | +171.8% | – |
| EPS growth | – | – | – | – | – | – | +181.3% | – |
| OPM % | – | – | – | -7.3% | 10.3% | 8.0% | 3.8% | 6.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Kabra Drugs reported sales of ₹92.74 crore and net profit of ₹4.96 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 92.74 | 5.33 | 5.75 | 4.96 | 2.09 |
| Mar 2025 | 0.00 | -1.72 | – | -1.09 | -0.46 |
| Mar 2024 | 0.00 | -0.74 | – | -0.74 | -1.69 |
| Mar 2023 | 0.00 | -0.35 | -3,400.00 | -0.34 | -0.77 |
| Mar 2022 | 0.00 | -0.18 | – | -0.19 | -0.43 |
| Mar 2021 | 0.00 | -0.15 | – | -0.18 | -0.41 |
| Mar 2020 | 0.00 | -0.05 | -150.00 | -0.06 | -0.14 |
| Mar 2019 | -0.04 | -0.13 | – | -0.16 | -0.36 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -102.2% | – | – | – | – | – | – | – |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | – | – |
| EPS growth | – | – | – | – | – | – | – | – |
| OPM % | – | -150.0% | – | – | -3400.0% | – | – | 5.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Kabra Drugs.
Get Free AI Stock Analysis FREE →Kabra Drugs gets LoI to establish pharmaceutical manufacturing facility in Chhattisgarh
Kabra Drugs shareholders approve name change and object clause alteration - scanx.trade
Kabra Drugs Limited Issues Postal Ballot Notice for Name Change to Aanjaay Industries Limited and MOA Object Expansion - scanx.trade
Kabra Drugs shares were last quoted at ₹18.35 (+0.5% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Kabra Drugs has a price-to-earnings (P/E) ratio of 5.86 and a price-to-book (P/B) ratio of 1.40. The industry P/E is 53.33.
The 52-week high of Kabra Drugs is ₹35.52 and the 52-week low is ₹15.50.
The market capitalisation of Kabra Drugs is about ₹44.48 crore.
In the latest quarter (Jun 2026), Kabra Drugs reported sales of ₹46.22 crore (+546.4%) and net profit of ₹2.12 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Kabra Drugs has a 3-year ROE of 8.00%, 3-year profit growth of 155.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Kabra Drugs belongs to the Pharmaceuticals & Drugs sector.